Evidence map›Paper›PMID 26739872›Full record

ArticleHypertension research : official journal of the Japanese Society of Hypertension2016

Augmented circadian rhythm of the intrarenal renin-angiotensin systems in anti-thymocyte serum nephritis rats.

Shinsuke Isobe, Naro Ohashi, Sayaka Ishigaki, Takayuki Tsuji, Yukitoshi Sakao, Akihiko Kato, Hiroaki Miyajima, Yoshihide Fujigaki, Akira Nishiyama, Hideo Yasuda

Open access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in Hypertension research : official journal of the Japanese Society of Hypertension, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
2.7field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Article
  3. Artificial light at night affects the daily profile of pulse pressure and protein expression in the thoracic aorta of rats.Hypertension research : official journal of the Japanese Society of Hypertension · 2024
    Article
  4. Current perspective on circadian function of the kidney.American journal of physiology. Renal physiology · 2024
    Review
  5. Review
  6. Review
  7. Article
  8. Circadian Control of Sodium and Blood Pressure Regulation.American journal of hypertension · 2021
    Review
  9. Article
  10. A disturbance beyond the barrier-chronic kidney disease allows angiotensinogen invasion.Hypertension research : official journal of the Japanese Society of Hypertension · 2021
    Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. The pivotal role of melatonin in ameliorating chronic kidney disease by suppression of the renin-angiotensin system in the kidney.Hypertension research : official journal of the Japanese Society of Hypertension · 2019
    Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Shinsuke IsobeInternal Medicine 1, Hamamatsu University School of Medicine, Hamamatsu, Japan.
Naro OhashiInternal Medicine 1, Hamamatsu University School of Medicine, Hamamatsu, Japan.
Sayaka IshigakiInternal Medicine 1, Hamamatsu University School of Medicine, Hamamatsu, Japan.
Takayuki TsujiInternal Medicine 1, Hamamatsu University School of Medicine, Hamamatsu, Japan.
Yukitoshi SakaoBlood Purification Unit, Hamamatsu University School of Medicine, Hamamatsu, Japan.
Akihiko KatoBlood Purification Unit, Hamamatsu University School of Medicine, Hamamatsu, Japan.
Hiroaki MiyajimaInternal Medicine 1, Hamamatsu University School of Medicine, Hamamatsu, Japan.
Yoshihide FujigakiInternal Medicine 1, Hamamatsu University School of Medicine, Hamamatsu, Japan.
Akira NishiyamaDepartment of Pharmacology, Kagawa University, Kagawa, Japan.
Hideo YasudaInternal Medicine 1, Hamamatsu University School of Medicine, Hamamatsu, Japan.
Hamamatsu University School of Medicine · JPKagawa University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We report that disturbance to the circadian rhythm of urinary angiotensinogen (AGT) excretion may lead to renal damage, hypertension and diurnal blood pressure (BP) variations. We aim to clarify the circadian rhythm of the intrarenal renin-angiotensin system (RAS) and its contribution to renal damage, hypertension and BP variations, and to evaluate whether the administration of RAS blockers influences the circadian rhythms of intrarenal RAS components. Anti-thymocyte serum (ATS) nephritis rats were used as a chronic progressive glomerulonephritis model (group A) and compared with control rats (group C). Other rats with ATS nephritis received olmesartan medoxomil (an angiotensin II (AngII) type 1 receptor (AT1R) blocker; group AO) or hydralazine (a vasodilator; group AH). The levels of intrarenal RAS components were evaluated every 6 h. The expression levels of intrarenal AGT, AngII and AT1R were increased in group A and peaked at the same time as BP and urinary protein excretion during the rest phase. The amplitude of the circadian fluctuation of these proteins was more increased in group A than in group C. The circadian fluctuation of these proteins was reduced in groups AO and AH. However, renal function, proteinuria and augmentation of intrarenal RAS components were reduced only in group AO. Intrarenal RAS components, such as AGT, AngII and AT1R proteins, were increased and the amplitude of the oscillations of these proteins was augmented in ATS nephritis rats. Interestingly, renal damage may be linked to the activation of the intrarenal RAS independent of the amplitude of its oscillations and BP.

Indexed as

Angiotensin IIAngiotensinogenAnimalsAntilymphocyte SerumCircadian RhythmDisease Models, AnimalHydralazineKidneyLymphocytesMaleNephritisOlmesartan MedoxomilRatsRats, WistarReceptor, Angiotensin, Type 1Renin-Angiotensin SystemAngiotensin IIAngiotensinogenAntilymphocyte SerumHydralazineOlmesartan MedoxomilReceptor, Angiotensin, Type 1

Identifiers

PMID26739872
OpenAlexW2222290802

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.